The use of chemotherapy was significantly higher in RB1CC1(−) patients than in RB1CC1(+) patients (p<0.0001), and was also higher in patients with triple-negative cancers than in those with non-triple-negative disease (Chi-square and Fisher's exact test, p<0.0001; data not shown). The gene discussed is RB1CC1; the disease is cancer.